TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Teva Pharmaceuticals
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva Pharmaceuticals submitted a New Drug Application to the FDA for a once-monthly subcutaneous olanzapine injectable suspension to treat schizophrenia in adults, based on Phase 3 SOLARIS trial results demonstrating efficacy and safety.

Insights
TSLA   negative

Part of the tech stock market correction


TEVA   positive

Company is advancing innovative treatment for schizophrenia, submitting a new drug application that could address critical unmet patient needs and expand their product portfolio